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ABSTRACT 24 
 25 
Amiloride and its derivative 5-(N-ethyl-N-isopropyl)amiloride (EIPA) were previously shown to 26 
inhibit coxsackievirus B3 (CVB3) RNA replication in cell culture, with two amino acid 27 
substitutions in the viral RNA-dependent RNA polymerase 3Dpol conferring partial resistance of 28 
CVB3 to the compounds (D. N. Harrison, E. V. Gazina, D. F. Purcell, D. A. Anderson, and S. 29 
Petrou, J. Virol. 82:1465-1473, 2008). Here, we demonstrate that amiloride and EIPA inhibit 30 
enzymatic activity of CVB3 3Dpol in vitro, affecting both VPg uridylylation and RNA elongation. 31 
Examination of the mechanism of inhibition of 3Dpol by amiloride showed that the compound 32 
acts as a competitive inhibitor, competing with incoming NTP and Mg2+. Docking analysis 33 
suggested a binding site for amiloride and EIPA in 3Dpol, which is located in close proximity to 34 
one of the Mg2+ ions and overlaps with the nucleotide binding site, thus explaining the observed 35 
competition. This is the first report of a molecular mechanism of action of non-nucleoside 36 
inhibitors against a picornaviral RNA-dependent RNA polymerase. 37 
 38 
39 
 3
INTRODUCTION 40 
 41 
The Picornaviridae are a family of positive-sense RNA viruses, which contains numerous 42 
human pathogens causing poliomyelitis, myocarditis, meningitis, hepatitis, common cold and 43 
other diseases. Viral genomic RNA is ~7500 nucleotides long and contains a 22-amino-acid 44 
peptide, VPg, covalently linked to the 5’ end, and a poly(A) tail at the 3’ end. Genome replication 45 
occurs via synthesis of a complementary, negative-sense, RNA strand, catalysed by the viral 46 
RNA-dependent RNA polymerase, 3Dpol, in association with a number of viral and host proteins. 47 
It is a complex process taking place in membrane-associated replication complexes in the 48 
cytoplasm of infected cells (reviewed in (5, 7, 23). The synthesis of both complementary and 49 
genomic RNA strands is initiated by attachment of two UMP nucleotides to a tyrosine residue of 50 
VPg, resulting in the production of VPg-pUpU. VPg uridylylation requires a template. In the case 51 
of genomic strand synthesis, an internal stem-loop in genomic RNA strand (cis-acting replication 52 
element, CRE) is used as a template, with subsequent translocation of VPg-pUpU to the 3’-end of 53 
the complementary strand and its elongation into a full-length genomic strand (9, 15, 16, 26). The 54 
complementary strand synthesis does not absolutely depend on CRE – it can also be templated by 55 
the poly(A) tail of the genomic strand (9, 15, 16, 26). 56 
VPg uridylylation and RNA elongation have been successfully reproduced in vitro using 57 
purified components. VPg uridylylation assays require 3Dpol, VPg, CRE or poly(A), UTP, and 58 
Mg2+ or Mn2+ (19, 20), with CRE-templated reaction stimulated by viral proteins 3CD or 3C (18, 59 
19), whereas an elongation assay contains an RNA primer instead of VPg (21).  60 
Coxsackievirus B3 (CVB3) is a picornavirus responsible for 14-32% of human myocarditis 61 
cases (1). Amiloride and its derivative 5-(N-ethyl-N-isopropyl)amiloride (EIPA) inhibit CVB3 62 
propagation in cell culture by inhibiting viral genome replication (11). Two amino acid 63 
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substitutions in 3Dpol (S299T or A372V) confer partial resistance of the virus to the compounds, 64 
suggesting that amiloride analogues may act as inhibitors of CVB3 3Dpol (11). Here, we show 65 
that amiloride and EIPA inhibit VPg uridylylation and RNA elongation by CVB3 3Dpol in vitro, 66 
acting as competitive inhibitors with respect to NTP and Mg2+. We further demonstrate that the 67 
S299T substitution in 3Dpol reduces the extent of inhibition of RNA elongation by amiloride and 68 
EIPA, thus recapitulating its effect on CVB3 inhibition in cell culture. This is the first report of a 69 
molecular mechanism of action of non-nucleoside inhibitors against a picornaviral RNA-70 
dependent RNA polymerase.   71 
 72 
MATERIALS AND METHODS 73 
 74 
Reagents. Expression and purification of wild-type (WT) and S299T CVB3 3Dpol, and 75 
CVB3 3C have been described previously (14, 17, 26). 3Dpol concentration was measured as in 76 
(26). CVB3 CRE was produced as described in (17). CVB3 VPg was synthesised by the Peptide 77 
Laboratory of Howard Florey Institute. Gel-purified 10-nt RNA (SSU) was purchased from 78 
Dharmacon, [γ-32P]ATP and [α-32P]UTP - from Perkin Elmer, and all other reagents - from 79 
Sigma. Amiloride was dissolved in DMSO at 500 mM concentration, and EIPA was dissolved in 80 
ethanol at 50 mM concentration. Final concentrations of DMSO or ethanol in reactions 81 
containing the compounds were 0.1% or 2%, respectively. Equal concentrations of the solvents 82 
were present in the no-compound controls. 83 
VPg uridylylation assay using poly(A) template. The assay was conducted essentially as 84 
described in (20). Reactions contained 1.2 μM CVB3 3Dpol (WT or S299T); poly(A) [equivalent 85 
of 70 μM AMP]; 50 μM VPg,; 10 μM 32P-labelled UTP (0.1μCi/μl); 50 mM HEPES-NaOH, pH 86 
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7.5; 6% glycerol; 11 mM 2-mercaptoethanol; 0.5 mM Mn(CH3COO) 2 and indicated 87 
concentrations of amiloride or EIPA. Reaction mixtures were assembled on ice without UTP, and 88 
incubated at 300C for 5 minutes. Reactions were then started by addition of 32P-labelled UTP and 89 
continued for 1 hour at 300C. The reactions were quenched by addition of EDTA to a final 90 
concentration of 50 mM, and reaction products were separated by 15% Tris-Tricine SDS-PAGE 91 
and quantified using BAS-5000 phosphorimager (Fujifilm) with Multi Gauge software.   92 
RNA elongation assay. SSU RNA was end-labelled using [γ-32P]ATP and T4 93 
polynucleotide kinase (New England Biolabs), followed by purification on Zeba 7K spin column 94 
(Pierce) equilibrated with water, as specified by the manufacturers’ instructions. The resulting 20 95 
μM 32P-labelled SSU was mixed with unlabelled SSU to 200 μM concentration, and annealed by 96 
heating to 900C for 1 min, followed by cooling to 100C at 50C/min rate.  97 
Unless specified otherwise, reactions contained 1.8 μM CVB3 3Dpol (WT or S299T); 20 98 
μM annealed 32P-labelled SSU (10 μM duplex); 10 μM ATP; 5 mM MgCl2; 50 mM HEPES-99 
NaOH, pH 7.5; 2% glycerol; 11 mM 2-mercaptoethanol and indicated concentrations of 100 
amiloride or EIPA. Reaction mixtures were assembled on ice and then incubated at 300C. The 101 
orders of assembly of reaction mixtures and incubation times are indicated. Reactions were 102 
quenched by addition of equal volume of 100 mM EDTA, 68% formamide, 0.02% bromphenol 103 
blue and 0.02% xylene cyanol in TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA), and 104 
heated to 650C for 5 min prior to loading on 20% polyacrylamide (1.5% bisacrylamide) gel 105 
containing TBE and 7% urea. The gels were visualised and quantified using BAS-5000 106 
phosphorimager (Fujifilm) with Multi Gauge software.   107 
VPg uridylylation assay using CVB3 CRE template. Reactions contained 1 µM 3Dpol 108 
(WT or S299T); 1 µM CVB3 3C; 1 µM CVB3 CRE; 50 µM CVB3 VPg; 250 µM 32P-labeled 109 
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UTP (0.1 µCi/µl); 50 mM HEPES-NaOH, pH 7.5; 10% glycerol; 12 mM 2-mercaptoethanol; 30 110 
mM NaCl; 0.7 mM Mg(CH3COO)2 and indicated concentrations of amiloride. Reaction mixtures 111 
were assembled on ice without 3Dpol and incubated at 300C for 5 minutes. Reactions were 112 
initiated by addition of 3Dpol, continued for 5 minutes at 300C, and quenched by addition of 113 
EDTA to a final concentration of 50 mM. Reaction products were separated by 15% Tris-Tricine 114 
SDS-PAGE and quantified using Typhoon phosphorimager (GE Healthcare).  115 
Molecular Modelling. CVB3 and poliovirus 3Dpol structures were downloaded from the 116 
Protein Data Bank (http://www.pdb.org/) and analysed for docking suitability (i.e. model 117 
completeness, resolution, visual analysis for conformational changes) using Pymol 118 
(http://pymol.org/). Four alternate structures were used in the docking studies based on their 119 
docking suitability and the presence of co-crystallised ligands (i.e. Mg2+, ATP, primer). These 120 
four had PDB codes 3CDW (10), 2ILY (24), 3OL7 and 3OL6 (8). All structures were aligned by 121 
their α-carbons, and for each structure water and non-physiological ligands (i.e. detergents, salts 122 
etc.) were removed. Whilst aligned, the coordinates of the two Mg2+ ions (crystallised in 123 
3OL7.pdb, (8)) and part of the VPg primer (crystallised in 3CDW.pdb, (10)) were extracted from 124 
their native crystal structure and merged into each alternate protein structure to create four 125 
different 3Dpol models for each X-ray structure: apo, with Mg2+, with VPg, with Mg2+ and VPg. 126 
Each model was then minimised until gradient convergence was reached under the MMFFs 127 
force-field. 128 
The unprotonated form and the three protonated tautomers of amiloride and EIPA were 129 
drawn and minimised under the Tripos force field in Sybylx1.2 (http://tripos.com/). ATP was 130 
extracted from 2ILY and minimised under the Tripos force field in Sybylx1.2. 131 
 Docking protomers were constructed for each of the 16 alternate models in Surflex-Dock 132 
(http://tripos.com). Each protomer was constructed by selecting a 15 Å sphere around Ser299, 133 
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adding a bloat of 3 Å and a threshold of 0.36 (blind docking using the entire 3Dpol molecule 134 
produced similar results). All ligands were docked into each protomer with 5 additional starting 135 
conformations per molecule, ring flexibility considered, the density of search increased to 9.0 136 
(default 3.0), and hydrogen and heavy atom protein movement of the receptor allowed. All other 137 
parameters were kept as default. The top 10 solutions were analysed visually in Sybylx1.2 and 138 
Pymol, with all figures generated in Pymol.   139 
 140 
RESULTS 141 
 142 
Amiloride and EIPA inhibit poly(A)-templated VPg uridylylation. To examine the 143 
hypothesis that amiloride and EIPA act as CVB3 3Dpol inhibitors (11), we assessed whether these 144 
compounds inhibit VPg uridylylation and/or RNA elongation by CVB3 3Dpol in vitro.  145 
Firstly, we conducted VPg uridylylation/RNA elongation assay using poly(A) template 146 
(20). The assay was performed on WT and S299T 3Dpol, in the presence of Mn2+ (no product was 147 
observed in the presence of Mg2+), using various concentrations of amiloride or EIPA, or no 148 
compound.  149 
Amiloride and EIPA reduced both VPg-pU(pU) and VPg-poly(U) production by WT and 150 
S299T 3Dpol in a concentration-dependent manner (Fig. 1), demonstrating that they inhibit VPg 151 
uridylylation. EIPA had a stronger inhibitory effect than amiloride (Fig. 1B), consistent with its 152 
stronger effect on CVB3 replication in cell culture (11). S299T 3Dpol was less susceptible to 153 
inhibition than WT 3Dpol (Fig. 1), consistent with the previous finding that S299T mutation 154 
confers partial resistance of CVB3 to the compounds (11).  155 
The effect of the compounds on VPg-poly(U) production appeared stronger than that on 156 
VPg-pU(pU) production (Fig. 1B), which could mean that they inhibit RNA elongation. 157 
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However, amiloride and EIPA had no obvious concentration-dependent effect on the length of 158 
the resulting poly(U) chain (Fig. 1A), which is contrary to what is expected in the case of 159 
inhibition of RNA elongation. These results were, therefore, inconclusive regarding the inhibition 160 
of RNA elongation. 161 
Amiloride and EIPA inhibit RNA elongation. To test whether amiloride and EIPA inhibit 162 
RNA elongation, we used symmetrical, self-annealing 10-nt RNA primer-template with uridine 163 
as the first templating base (SSU, (2)): 164 
                   5’-GCAUGGGCCC 165 
                                   CCCGGGUACG-5’.  166 
ATP was used as the only nucleotide substrate to analyse single nucleotide incorporation 167 
into SSU. In the presence of Mg2+, 3Dpol binds to SSU duplex and incorporates a single AMP at 168 
the 3’-terminus of one RNA strand with rapid, pre-steady-state burst kinetics (2, 3). This is 169 
followed by slow dissociation of 3Dpol from the product (rate-limiting step of steady-state phase) 170 
and subsequent rebinding to a new SSU duplex followed by AMP incorporation (2).  171 
We measured steady-state kinetics of 11-nt RNA production (formed by addition of one 172 
AMP to 10-nt RNA primer) by WT and S299T 3Dpol in the absence or presence of various 173 
concentrations of amiloride or EIPA. 3Dpol was pre-incubated with SSU duplex (used in 5.5-fold 174 
excess of 3Dpol) and the compounds in the presence of Mg2+ for 6 min at 300C, after which 175 
reactions were initiated by addition of ATP, continued for 10, 18, 26 or 34 minutes and then 176 
quenched (Fig. 2A). The amount of AMP incorporated into SSU during the pre-steady-state burst 177 
was determined by plotting 11-nt RNA production in each reaction as a function of the reaction 178 
time and fitting data points to a line. The Y-intercept of each line defined the amount of AMP 179 
incorporated during the pre-steady-state burst (Fig. 2B). Both compounds inhibited the amplitude 180 
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of the pre-steady-state burst in a concentration-dependent manner (Fig. 2C), thus demonstrating 181 
that they inhibit RNA elongation.  182 
EIPA had a stronger effect on the pre-steady-state burst of AMP incorporation than 183 
amiloride, and WT 3Dpol was more susceptible to the inhibition than S299T 3Dpol (Fig. 2C), 184 
consistent with the data on CVB3 replication in cell culture (11). The difference in the 185 
susceptibility to inhibition between WT and S299T 3Dpol (3.6-fold difference in IC50 for 186 
amiloride and 4.4-fold for EIPA, Fig. 2) was significantly more pronounced than that observed 187 
for VPg-pU(pU) production (1.3- and 2-fold difference in IC50 for amiloride and EIPA, 188 
respectively, Fig. 1).  189 
In contrast to inhibition of the pre-steady-state burst amplitude, the effects of the 190 
compounds on the steady-state rate constant were small (data not shown) and difficult to interpret 191 
due to the occurrence of multiple events (i.e. dissociation, association and nucleotide 192 
incorporation). Our following studies were, therefore, focused on the pre-steady-state burst 193 
amplitude. 194 
Inhibitory effect on RNA elongation depends on the order of addition. As a first step 195 
towards elucidation of the mechanism of inhibition of RNA elongation, we examined how the 196 
order of assembly of the reaction mixture influences the effect of the compounds on pre-steady-197 
state AMP incorporation into SSU. We pre-incubated 3Dpol with SSU and the compounds in the 198 
absence of Mg2+ for 6 min at 300C, after which reactions were started by the addition of ATP and 199 
Mg2+. Dose-response curves for the inhibition of pre-steady-state burst amplitude (Fig. 3) were 200 
obtained as described above. The results showed that amiloride and EIPA were ~7-fold more 201 
effective when they were incubated with SSU and WT 3Dpol in the absence of Mg2+ prior to ATP 202 
addition compared to the incubation in the presence of  Mg2+ (Fig. 3 and 2C). This result 203 
suggested that the compounds might compete with Mg2+ for the binding site. The difference 204 
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between WT and S299T 3Dpol was also more pronounced under these conditions (5.9-fold for 205 
amiloride and 5.8-fold for EIPA, Fig. 3). 206 
Further order-of-addition experiments were conducted on WT 3Dpol using 500 μM 207 
amiloride. Adding amiloride to pre-assembled SSU-3Dpol complexes (order of addition: SSU + 208 
3Dpol + Mg2+ → amiloride → ATP) resulted in 80% inhibition of pre-steady-state AMP 209 
incorporation into SSU, compared to 84% inhibition when amiloride was added prior to the 210 
complex assembly (Table 1). This result showed that amiloride can bind to SSU-3Dpol complex 211 
and that it is unlikely to affect complex formation. 212 
Adding amiloride at the same time as ATP in the presence of Mg2+ (order of addition: SSU 213 
+ 3Dpol + Mg2+ → ATP + amiloride) reduced the extent of inhibition from 84% to 9% (Table 1). 214 
This suggested that amiloride might compete with ATP for the binding site. However, adding 215 
amiloride at the same time as ATP in the absence of Mg2+ (order of addition: SSU + 3Dpol + ATP 216 
+ amiloride → Mg2+) resulted in 96% inhibition, the same effect as when the compound was 217 
added prior to ATP (order of addition: SSU + 3Dpol + amiloride → ATP + Mg2+, Table 1). The 218 
dependence of inhibitory effect of amiloride, when added together with ATP, on the order of 219 
Mg2+ addition indicated that amiloride may interact with 3Dpol slower than does ATP. In this 220 
case, in the presence of Mg2+ the chemical reaction of AMP incorporation into SSU would occur 221 
too fast to be inhibited by amiloride, whereas the 6-minute incubation in the absence of Mg2+ 222 
would allow amiloride to compete with ATP. 223 
Altogether, the order-of-addition experiments suggested that amiloride may be a slow-224 
binding inhibitor competing with ATP and Mg2+. 225 
Amiloride is a slow inhibitor. To examine the kinetics of 3Dpol inhibition by amiloride, we 226 
assembled SSU-3Dpol complexes and incubated them with amiloride for various periods of time, 227 
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in the presence of Mg2+, prior to starting reactions with ATP. The inhibitory effect of amiloride 228 
on both WT and S299T 3Dpol gradually increased with the increase in the incubation time (Fig. 229 
4). The calculated inhibition half-time values were ~ 35 sec for WT 3Dpol with 500 μM amiloride 230 
and S299T 3Dpol with 1000 μM amiloride, and ~70 sec for WT 3Dpol with 250 μM amiloride and 231 
S299T 3Dpol with 500 μM amiloride (Fig. 4). These data demonstrated that amiloride inhibits 232 
3Dpol slowly, possibly due to steric constraints of the binding site or a conformational change 233 
occurring in the process. They also showed that S299T 3Dpol is inhibited 2-fold slower than WT 234 
3Dpol by the same concentration of amiloride, consistent with the partial resistance to inhibition 235 
of RNA elongation conferred by this mutation.  236 
Amiloride competes with ATP and Mg2+. To test the hypothesis that amiloride may 237 
compete with NTP for the binding site on 3Dpol, we conducted a competition assay on the WT 238 
enzyme using various concentrations of ATP and amiloride. We incubated 3Dpol, SSU, amiloride 239 
and ATP for 5 minutes at 300C in the absence of Mg2+ to allow binding, after which reactions 240 
were started by the addition of 5 mM MgCl2. The amplitude of pre-steady-state AMP 241 
incorporation into SSU was quantified and plotted as a function of ATP concentration (Fig. 5A 242 
and 5B). The data showed that the inhibitory effect of amiloride decreases with an increase in 243 
ATP concentration (Fig. 5B), suggesting that amiloride competes with ATP for the binding site. 244 
This result also demonstrated that Mg2+ is not required for binding of SSU, ATP and amiloride to 245 
3Dpol (otherwise competition between ATP and amiloride would not be observed under these 246 
conditions).  247 
A similar competition assay was conducted using various concentrations of Mg2+ and 248 
amiloride to test the hypothesis that amiloride may compete with Mg2+ for the binding site. WT 249 
3Dpol, SSU, amiloride and Mg2+ were incubated for 5 min at 300C, after which reactions were 250 
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started by the addition of 10 μM ATP (Fig. 5C and 5D). The results were more complicated to 251 
interpret than those from the ATP competition assay, perhaps because the stoichiometry of the 252 
complexes involves two Mg2+ ions at two functionally distinct sites (see Fig. 8). With amiloride 253 
concentrations of 50 and 125 μM the inhibition decreased with an increase in Mg2+ concentration 254 
from 0.5 to 3.5 mM (Fig. 5D). The response was saturated above 3.5 mM Mg2+ as evidenced by 255 
the levelling off (Fig. 5D). 500 μM amiloride was too high a concentration to observe a 256 
significant effect of Mg2+ concentration on the level of inhibition by amiloride (Fig. 5D). In total, 257 
these data are consistent with competition between amiloride and Mg2+ for binding to 3Dpol. Of 258 
note, the effect of Mg2+ concentration on the enzymatic activity of 3Dpol in the absence of 259 
amiloride (i.e a concentration-dependent increase in AMP incorporation followed by a decrease, 260 
Fig. 5C) is a pattern for optimum Mg2+ concentration observed in nucleic acid polymerases, 261 
including CVB3 3Dpol (10). 262 
Amiloride inhibits CRE-templated VPg uridylylation. The above results suggested that 263 
amiloride inhibits RNA elongation by acting as a competitive inhibitor with respect to NTP and 264 
Mg2+. The VPg uridylylation assay using poly(A) template indicated that it also inhibits VPg 265 
uridylylation, however, that assay could only be done using Mn2+ instead of Mg2+. We have, 266 
therefore, examined inhibition of VPg uridylylation by amiloride under more biologically 267 
relevant conditions by using CRE template in the presence of Mg2+ (17). The assay was 268 
conducted on WT and S299T 3Dpol. Reaction mixtures including CVB3 3C, CVB3 CRE, CVB3 269 
VPg, 250 µM UTP, 0.7 mM Mg2+ and various concentrations of amiloride were incubated at 270 
300C for 5 minutes. Reactions were initiated by the addition of 3Dpol, incubated for 5 minutes and 271 
then quenched. 250 µM UTP and 0.7 mM Mg2+ correspond to the physiological concentrations of 272 
UTP and free Mg2+ in mammalian cells (22, 25). The results demonstrated that amiloride 273 
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effectively inhibited VPg uridylylation under these conditions (Fig. 6), with the IC50 being lower 274 
than that for VPg uridylylation using poly(A) template (Fig. 1). Surprisingly, there was no 275 
difference in the inhibitory effect between WT and S299T 3Dpol (Fig. 6). Changing experimental 276 
conditions, such as incubation time, UTP and Mg2+ concentrations (i.e. using 10 µM UTP and 5 277 
mM Mg2+) and the order of addition (i.e. starting the reaction with UTP and Mg2+) produced 278 
similar results to those shown in Fig. 6 (data not shown). 279 
Molecular basis for inhibition. CVB3 and poliovirus 3Dpol structures (3CDW, 2ILY, 280 
3OL6 and 3OL7) were downloaded from the Protein Data Bank and analysed for docking 281 
suitability. Similar docking results were obtained irrespective of which 3Dpol structure was used, 282 
or whether unprotonated amiloride and EIPA were docked or their protonated tautomers. Thus, 283 
for simplicity, only the unprotonated forms of EIPA and amiloride docked into structures based 284 
on the 3CDW entry will be described in detail. 285 
Amiloride and EIPA were able to dock into each of the four 3Dpol structures: apo, with 286 
Mg2+, with VPg, with Mg2+ and VPg (Table 2). Notably, when the Mg2+ ions were present, a 287 
consistent binding pose was not observed for either compound, suggesting that Mg2+ inhibits 288 
compound binding. Also, when Mg2+ was present, the Surflex scoring function, the C-score (the 289 
unitless consensus score which integrates a number of popular scoring functions to indicate the 290 
affinity of ligands bound to a receptor), was significantly reduced for the top docked solution 291 
(Table 2). 292 
Where a consistent solution was obtained (apo and VPg configurations of 3Dpol), both 293 
amiloride and EIPA docked with hydrogen bonds to amino acid residues Ala57, Ser173, Ser60 294 
and Lys61 (Fig. 7). The amino group of amiloride, which is capped by a branched carbon chain 295 
(i.e. N-ethyl-N-isopropyl group) in EIPA, hydrogen bonded to Ser289. Hydrophobic interactions 296 
were found between EIPA or amiloride and Ala57, Ile58, Lys172, Ser173 and Arg174. 297 
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Additional hydrophobic interactions were found between the N-ethyl-N-isopropyl group of EIPA 298 
and Lys61, Asp238 and Ser289 (Fig. 7). The carbonylguanidino moiety of each compound was 299 
found in two possible orientations due to its flexibility. The C-scores for both orientations were 300 
very similar, thus both are plausible solutions. However, one orientation (shown in Fig. 7A) had a 301 
higher C-score for EIPA, 7.7121 versus 7.217, whereas the alternative orientation (shown in Fig. 302 
7B) had a higher C-score for amiloride, 7.3372 versus 7.087. 303 
The position of docked amiloride or EIPA was distinct from where VPg and the RNA 304 
template interact with 3Dpol (8), suggesting that the presence of RNA template and/or VPg should 305 
not have a significant effect on binding (Table 3 and Fig. 8). This was consistent with our finding 306 
that amiloride can bind to pre-assembled SSU-3Dpol complex. Amiloride and EIPA were also 307 
distant from Ser299 (and Ala372, Table 3). Our data showing that S299T mutation affects 308 
inhibition of RNA elongation but not CRE-templated VPg uridylylation by amiloride are 309 
consistent with Ser299 not being part of the compounds’ binding site. 310 
The pyrazine ring of amiloride and EIPA was very close to the binding site of one of the 311 
Mg2+ ions causing repulsive interactions (Table 3 and Fig. 8), consistent with the difficulty of the 312 
docking program to obtain a consistent, high scoring docking pose in the presence of Mg2+ (Table 313 
2). This was enhanced for EIPA because its N-ethyl-N-isopropyl group encroached on the 314 
position of the Mg2+ ion (Table 3 and Fig. 8). 315 
ATP docked into the same position in all 3Dpol configurations (i.e. apo, with Mg2+, with 316 
VPg, with VPg and Mg2+), in an orientation observed in the crystal structures (Fig. 8). There was 317 
overlap between the binding site of ATP and the binding sites of amiloride and EIPA (Fig. 8), 318 
suggesting that the compounds compete with NTP for the binding to 3Dpol. The docking score of 319 
ATP was significantly higher than those of amiloride or EIPA (Table 2), suggesting that ATP 320 
binds to 3Dpol with higher affinity than amiloride or EIPA. 321 
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DISCUSSION 322 
 323 
Amiloride and EIPA have been shown to inhibit CVB3 RNA replication in cell culture, 324 
with amino acid substitutions in 3Dpol (S299T or A372V) conferring partial resistance of CVB3 325 
to the compounds, suggesting that the antiviral effect of the compounds may be due to 3Dpol 326 
inhibition (11).  327 
Here, we demonstrated that amiloride and EIPA inhibit VPg uridylylation and RNA 328 
elongation by CVB3 3Dpol in vitro. Examination of the mechanism of inhibition of 3Dpol by 329 
amiloride showed that the compound acts as a competitive inhibitor, competing with incoming 330 
NTP and Mg2+ (Fig. 5). Docking analysis suggested the most likely binding site for amiloride and 331 
EIPA in 3Dpol (Fig. 8). Binding of the compounds in this site would interfere with binding of 332 
NTP and one of the Mg2+ ions, thus explaining the observed competition (Fig. 8). 333 
 Previous studies have shown that amiloride inhibits a number of protein kinases via 334 
competition with ATP (4, 6, 12). Thus, this compound has affinity for nucleotide-binding sites of 335 
different enzymes.  336 
Compared to amiloride, EIPA was a more potent 3Dpol inhibitor (Fig. 1-3), consistent with 337 
its stronger effect on WT CVB3 replication in cell culture (11). The docking analysis suggested 338 
that this is due to the additional hydrophobic interactions between the branched carbon chain of 339 
EIPA and three amino acid residues of 3Dpol (Fig. 7). The difference between amiloride and 340 
EIPA in the inhibition of CVB3 replication in cell culture (30-fold difference in IC50, (11)) was 341 
more pronounced than that in the inhibition of CVB3 3Dpol in the in vitro assays, likely due to 342 
different intracellular accumulation of the two compounds. 343 
CRE-templated VPg uridylylation was inhibited by amiloride in the presence of 344 
physiological concentrations of UTP and Mg2+ (Fig. 6), with an IC50 similar to that observed for 345 
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CVB3 inhibition in cell culture (i.e. 60 μM, (11)). This suggests that inhibition of VPg 346 
uridylylation is a part of the mechanism of inhibition of CVB3 RNA replication in cell culture.  347 
Single AMP incorporation into SSU was inhibited by amiloride more effectively than VPg 348 
uridylylation when the compound was allowed to bind to 3Dpol-SSU complex prior to the 349 
addition of ATP and Mg2+ (Fig. 3). However, the inhibitory effect of amiloride was strongly 350 
reduced when the compound was added to 3Dpol-SSU complex together with ATP in the presence 351 
of Mg2+ due to slow inhibition kinetics compared to rapid nucleotide incorporation (Fig. 4). 352 
Because a small inhibitory effect on single nucleotide addition can be magnified greatly over 353 
more than 7400 nucleotide additions in the course of RNA elongation, we conclude that it is 354 
likely that amiloride and EIPA inhibit CVB3 RNA elongation in cell culture.  355 
Additional evidence supporting this conclusion comes from inhibition of S299T 3Dpol 356 
compared to the WT. The S299T mutation confers partial resistance of CVB3 to amiloride and 357 
EIPA in cell culture (11). Furthermore, this mutation was shown to reduce the inhibition of 358 
CVB3 RNA synthesis in cell culture by amiloride (14). Single AMP incorporation into SSU by 359 
S299T 3Dpol was less inhibited by amiloride and EIPA than that by the WT enzyme (Fig. 2 and 360 
3), recapitulating the cell culture data. In contrast, the extent of inhibition of CRE-templated VPg 361 
uridylylation by amiloride was the same for the two enzymes (Fig. 6). When poly(A) was used as 362 
a template for VPg uridylylation, a small difference in IC50 between S299T 3Dpol and the WT 363 
was observed for amiloride (1.3-fold) and a larger one for EIPA (2-fold, Fig. 1), but this assay is 364 
less biologically relevant than the assay using CRE template. Our overall conclusion is, therefore, 365 
that both VPg uridylylation and RNA elongation are inhibited by amiloride and EIPA in cell 366 
culture, with RNA elongation being the main process rescued by the S299T mutation in 3Dpol.  367 
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Our finding that VPg uridylylation is less influenced by the S299T mutation than is RNA 368 
elongation in terms of resistance to amiloride is not surprising in light of the data on the related 369 
poliovirus 3Dpol demonstrating that the VPg uridylylation activity is distinct from the RNA 370 
elongation activity, with differing responses to a mutation. Substitution of N297 in poliovirus 371 
3Dpol (homologous to N298 in CVB3 3Dpol, next to S299) had different effects on VPg 372 
uridylylation and RNA elongation, revealing the distinct specificities of initiation and RNA 373 
elongation complexes (13). 374 
An additional factor contributing to virus resistance conferred by the S299T mutation is the 375 
fidelity of CVB3 3Dpol. Amiloride increases the error rate of WT 3Dpol; whereas S299T 3Dpol has 376 
lower fidelity than the WT, but it remains unaffected by the compound (14). Interestingly, virus 377 
resistance conferred by A372V substitution is due solely to higher fidelity of the A372V 3Dpol 378 
compared to the WT enzyme because this mutation does not affect the inhibition of RNA 379 
synthesis by the compound (14). 380 
In summary, our data strongly suggest that amiloride and EIPA inhibit CVB3 replication in 381 
cell culture by inhibiting VPg uridylylation and RNA elongation, with RNA elongation being the 382 
main process rescued by the S299T mutation in 3Dpol. The compounds act as competitive 383 
inhibitors of CVB3 3Dpol, competing with NTPs and Mg2+ for binding to the active site of the 384 
enzyme. This is the first report of a molecular mechanism of action of non-nucleoside inhibitors 385 
against a picornaviral RNA-dependent RNA polymerase. 386 
 387 
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FIGURE LEGENDS  474 
FIG. 1. Inhibition of VPg-pU(pU) and VPg-poly(U) production by amiloride and EIPA. 475 
Reactions contained 1.2 μM CVB3 3Dpol (WT or S299T), poly(A) [equivalent of 70 μM AMP]; 476 
50 μM VPg; 10 μM 32P-labelled UTP, 0.5 mM Mn(CH3COO)2 and indicated concentrations of 477 
amiloride or EIPA. Reactions were started by addition of UTP and incubated at 300C for 1 hour. 478 
Reaction products were then separated by gel electrophoresis, and VPg-pU(pU) and VPg-poly(U) 479 
production was quantified using a phosphorimager. (A) Representative gel images. Positions of 480 
UTP, VPg-pU(pU) and VPg-poly(U) are marked. (B) Dose-response curves for amiloride (left) 481 
and EIPA (right). ■, VPg-pU(pU) production by WT 3Dpol; ▲, VPg-poly(U) production by WT 482 
3Dpol; □, VPg-pU(pU) production by S299T 3Dpol; △, VPg-poly(U) production by S299T 3Dpol. 483 
IC50, 50% inhibitory concentrations calculated using equation Y=100/(1+10^((logIC50-484 
logX)*HillSlope)) (GraphPad Prism). The data points are averages + SEM from 3 independent 485 
experiments. 486 
 487 
FIG. 2. Inhibition of AMP incorporation into SSU by amiloride and EIPA. 1.8 μM CVB3 488 
3Dpol (WT or S299T) was pre-incubated with 20 μM 32P-labelled SSU, 5 mM MgCl2 and 489 
indicated concentrations of amiloride or EIPA for 6 min at 300C. Reactions were started by 490 
addition of 10 μM ATP and continued for 10, 18, 26 or 34 minutes. The 11-nt product was then 491 
separated from 10-nt SSU by gel electrophoresis, and its amount was quantified using a 492 
phosphorimager. (A) Representative gel images for amiloride treatment. Positions of 10-nt and 493 
11-nt RNAs are marked. (B) Steady-state kinetics of 11-mer production in reactions shown in A. 494 
Data points are fitted to lines. Y-Intercept of each line defines amplitude of AMP incorporation 495 
into SSU during the pre-steady-state burst. Amiloride concentrations: ●, 0 μM; ■, 62.5 μM; ▲, 496 
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125 μM; ◆, 250 μM; △, 500 μM. (C) Dose-response curves for inhibition of pre-steady-state 497 
AMP incorporation into SSU by amiloride and EIPA. ■, WT 3Dpol + amiloride; ▲, WT 3Dpol + 498 
EIPA; □, S299T 3Dpol + amiloride; △, S299T 3Dpol + EIPA. IC50, 50% inhibitory concentrations 499 
calculated using equation Y=100/(1+10^((logIC50-logX)*HillSlope)) (GraphPad Prism). The data 500 
points are averages + SEM from 4 independent experiments.  501 
 502 
FIG. 3. Effect of order of Mg2+ addition on inhibition of pre-steady-state AMP 503 
incorporation into SSU by amiloride and EIPA. 1.8 μM CVB3 3Dpol (WT or S299T) was pre-504 
incubated with 20 μM 32P-labelled SSU and indicated concentrations of amiloride or EIPA for 6 505 
min at 300C. Reactions were started by addition of 10 μM ATP and 5 mM MgCl2. Pre-steady-506 
state burst amplitude of AMP incorporation into SSU was measured and quantified as described 507 
in Fig. 2. IC50, 50% inhibitory concentrations calculated using equation Y=100/(1+10^((logIC50-508 
logX)*HillSlope)) (GraphPad Prism). ■, WT 3Dpol + amiloride; ▲, WT 3Dpol + EIPA; □, S299T 509 
3Dpol + amiloride; △, S299T 3Dpol + EIPA. The data points are averages + SEM from 3 510 
independent experiments.  511 
 512 
FIG. 4. Dependence of inhibitory effect of amiloride on incubation time before ATP 513 
addition. Amiloride was added to pre-assembled SSU-3Dpol complexes and incubated at 300C C 514 
for indicated periods of time prior to starting reactions with 5 mM ATP. The reactions were 515 
allowed to proceed for 20 seconds, after which the 11-nt product was separated from SSU by gel 516 
electrophoresis, and its amount was quantified using a phosphorimager. Product formation, 517 
normalized to no amiloride controls, was plotted as a function of incubation time before ATP 518 
addition. Lines are fits to the single exponential model P=A*exp(-kobs*t)+C where A is the 519 
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amplitude, kobs is the observed rate constant, t is the independent variable time and C is the 520 
endpoint. Inhibition half-times were calculated from ln2/kobs. ▲, WT 3Dpol + 250 μM amiloride; 521 
■, WT 3Dpol + 500 μM amiloride; □, S299T 3Dpol + 500 μM amiloride; ◇, S299T 3Dpol + 1 mM 522 
amiloride. The data points are averages + SEM from 2 independent experiments.  523 
 524 
FIG. 5. Competition assays. (A and B) Amiloride-ATP competition assay. 1.8 μM WT 525 
3Dpol, 20 μM SSU, 0.1-5 mM ATP, and 0-500 μM amiloride were incubated for 5 minutes at 526 
300C in the absence of Mg2+. Reactions were then started by addition of 5 mM MgCl2. (C and D) 527 
Amiloride-Mg2+ competition assay. 1.8 μM WT 3Dpol, 20 μM SSU, 0.5-5 mM MgCl2, and 0-500 528 
μM amiloride were incubated for 5 minutes at 300C. Reactions were then started by addition of 529 
10 μM ATP. (A-D) Pre-steady-state burst amplitude of AMP incorporation into SSU was 530 
measured and quantified as described in Fig. 2. (A and C) Concentration of AMP incorporated 531 
during pre-steady-state burst is plotted as a function of ATP or MgCl2 concentration, 532 
respectively. (B) For each ATP concentration, AMP incorporation in the presence of amiloride 533 
was calculated as % of untreated using average values in A. The data for each concentration of 534 
amiloride were fit to a line. (D) For each MgCl2 concentration, AMP incorporation in the 535 
presence of amiloride was calculated as % of untreated using average values in C. Amiloride 536 
concentrations: ●, 0 μM; ◆, 50 μM; ■, 125 μM; ▲, 500 μM. 537 
 538 
FIG. 6. Inhibition of CRE-templated VPg-pU(pU) production by amiloride. Reactions 539 
contained 1 μM CVB3 3Dpol (WT or S299T), 1μM CVB3 3C; 1 μM CRE; 50 μM VPg; 250 μM 540 
32P-labelled UTP, 0.7 mM Mg(CH3COO)2 and indicated concentrations of amiloride. Reactions 541 
were started by addition of 3Dpol and incubated at 300C for 5 minutes. Reaction products were 542 
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then separated by gel electrophoresis, and VPg-pU(pU) production was quantified using a 543 
phosphorimager. (A) Representative gel images. Positions of UTP and VPg-pU(pU) are marked. 544 
(B) Dose-response curves for WT (●) and S299T (○) 3Dpol. IC50, 50% inhibitory concentrations 545 
calculated using equation Y=100/(1+10^((logIC50-logX)*HillSlope)) (GraphPad Prism). The data 546 
points are averages + SEM from 3 independent experiments.  547 
 548 
FIG. 7. Stereo views of the docked solutions of EIPA (A) and amiloride (B) into the apo 549 
form of 3Dpol displaying the residues involved in important interactions. (A) Hydrogen bonds are 550 
displayed in yellow dashed lines between EIPA (purple sticks) and Ala57, Ser60, Lys61 and 551 
Ser173. (B) Hydrogen bonds are displayed in yellow dashed lines between amiloride (magenta 552 
sticks) and Ala57, Ser60, Lys61, Ser173 and Ser289. 553 
 554 
FIG. 8. 3Dpol (grey cartoon) showing the positions of the RNA template (red sticks), VPg 555 
(orange sticks), Mg2+ ions (purple spheres), ATP (green sticks) and residues Ala372 and Ser299 556 
(blue sticks), in relation to the docking position of amiloride (magenta sticks) and EIPA (mauve 557 
sticks). Amiloride and EIPA are distant from the RNA template and VPg binding sites, thus both 558 
are not expected to have an effect on binding. However, the close proximity of amiloride and 559 
EIPA to one of the Mg2+ ions and an overlap with the nucleotide binding site suggest that the 560 
presence of Mg2+ and/or ATP would affect compound binding. 561 
 562 
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TABLE 1. Summary of order-of-addition data using WT 3Dpol and 500 μM amiloride 563 
Order of addition Pre-steady-state burst amplitude,  % of untreated 
                                                               6'300C 
SSU + 3Dpol + Mg2+ + amiloride  →  ATP                         15.5+1.4 a 
                                            6'300C 
SSU + 3Dpol + amiloride  →  ATP + Mg2+                           6.3+0.9 b 
                                                 5'300C                       6'300C 
SSU + 3Dpol + Mg2+  →  amiloride  →  ATP                         20.2+4.1 
                                                  6'300C 
SSU + 3Dpol + Mg2+  →  ATP + amiloride                         91.2+2.5 
                                                             6'300C 
SSU + 3Dpol + ATP + amiloride  →  Mg2+                           4.1+0.3 
a Data presented in Fig. 2C 564 
b Data presented in Fig. 3 565 
 566 
TABLE 2. C-scores for the docking of the ligands into the alternate 3Dpol configurationsa 567 
3Dpol configuration EIPA C-score  
(top solution) 
Amiloride C-score 
(top solution) 
ATP C-score 
(top solution) 
Apo 7.7121 7.3372 9.8231 
Mg2+ 5.5377 4.3044 12.3604 
Mg2+ and VPg  5.1489 5.0479 9.6415 
VPg  7.7121 7.2949 9.7121 
 568 
a A higher C-score is a reflection of higher affinity of the ligand to 3Dpol. 569 
 570 
 571 
572 
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TABLE 3. Distances from the ligands to substructuresa 573 
 Distance to amiloride (Å) Distance to EIPA (Å) 
Ala57 2.4 2.6 
Ser60 2.5 3.3 
Lys61 3.2 2.9 
Ser173 2.8 2.2 
Ser289 3.3 3.1 
Ile58  3.2 3.0 
Lys172 2.9 3.1 
Arg174 2.4 2.7 
Asp238 3.8 3.5 
Ser299 13.0 13.3 
Ala372 20.0 21.0 
VPg 28.0 29.4 
RNA template 7.3 6.4 
Mg2+ ion 5.3 2.5 
 574 
a All measurements are an indication of heavy atom distances from the ligand to the 575 
closest heavy atom in the substructure. 576 
 577 
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